have a medical history or family history of convulsion, epilepsy, encephalopathy and psychosis. be allergic to any component of the research vaccines, or used to have a history of hypersensitivity or serious reactions to vaccination. women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan within six months. have acute febrile diseases and infectious diseases. have severe chronic diseases or condition in progress cannot be smoothly controlled, such as asthma, diabetes, thyroid disease congenital or acquired angioedema / neuroedema. have the history of urticaria 1 year before receiving the trial vaccine. have asplenia or functional asplenia. have thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection). have the history of immunosuppressive therapy, anti allergy therapy, cytotoxic therapy or inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and acute corticosteroid therapy without dermatitis) over the past 6 months. have received blood products within 4 months before injection of trial vaccines. have received another investigational product within one month before injection of trial vaccine. have received attenuated vaccine within 1 month before injection of trial vaccine except the recombinant ad5 vectored covid-19 vaccine. have received subunit or inactivated vaccine within 14 days before the vaccination with trial vaccine. under anti tuberculosis treatment. not be able to follow the protocol, or not be able to understand the informed consent according to the researcher's judgment, due to various medical, psychological, social or other conditions.

have a medical history or family history of convulsion, epilepsy, encephalopathy and psychosis. be allergic to any component of the research vaccines, or used to have a history of hypersensitivity or serious reactions to vaccination. women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan within six months. have acute febrile diseases and infectious diseases. have severe chronic diseases or condition in progress cannot be smoothly controlled, such as asthma, diabetes, thyroid disease congenital or acquired angioedema / neuroedema. have the history of urticaria 1 year before receiving the trial vaccine. have asplenia or functional asplenia. have thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection). have the history of immunosuppressive therapy, anti allergy therapy, cytotoxic therapy or inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and acute corticosteroid therapy without dermatitis) over the past 6 months. have received blood products within 4 months before injection of trial vaccines. have received another investigational product within one month before injection of trial vaccine. have received attenuated vaccine within 1 month before injection of trial vaccine except the recombinant ad5 vectored covid-19 vaccine. have received subunit or inactivated vaccine within 14 days before the vaccination with trial vaccine. under anti tuberculosis treatment. not be able to follow the protocol, or not be able to understand the informed consent according to the researcher's judgment, due to various medical, psychological, social or other conditions.

- have the medical history or family history of convulsion, epilepsy, encephalopathy and psychosis. - be allergic to any component of the research vaccines, or used to have a history of hypersensitivity or serious reactions to vaccination. - women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan within six months. - have acute febrile diseases and infectious diseases. - have severe chronic diseases or condition in progress cannot be smoothly controlled, such as asthma, diabetes, thyroid disease - congenital or acquired angioedema / neuroedema. - have the history of urticaria 1 year before receiving the trial vaccine. - have asplenia or functional asplenia. - have thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection). - have needle sickness. - have the history of immunosuppressive therapy, anti allergy therapy, cytotoxic therapy or inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and acute corticosteroid therapy without dermatitis) over the past 6 months. - have received blood products within 4 months before injection of trial vaccines. - have received another investigational product within one month before injection of trial vaccine. - have received attenuated vaccine within 1 month before injection of trial vaccine except the recombinant ad5 vectored covid-19 vaccine. - have received subunit or inactivated vaccine within 14 days before the vaccination with trial vaccine. - under anti tuberculosis treatment. - not be able to follow the protocol, or not be able to understand the informed consent according to the researcher's judgment, due to various medical, psychological, social or other conditions.

- have the medical history or family history of convulsion, epilepsy, encephalopathy and psychosis. - be allergic to any component of the research vaccines, or used to have a history of hypersensitivity or serious reactions to vaccination. - women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan within six months. - have acute febrile diseases and infectious diseases. - have severe chronic diseases or condition in progress cannot be smoothly controlled, such as asthma, diabetes, thyroid disease - congenital or acquired angioedema / neuroedema. - have the history of urticaria 1 year before receiving the trial vaccine. - have asplenia or functional asplenia. - have thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection). - have needle sickness. - have the history of immunosuppressive therapy, anti allergy therapy, cytotoxic therapy or inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and acute corticosteroid therapy without dermatitis) over the past 6 months. - have received blood products within 4 months before injection of trial vaccines. - have received another investigational product within one month before injection of trial vaccine. - have received attenuated vaccine within 1 month before injection of trial vaccine except the recombinant ad5 vectored covid-19 vaccine. - have received subunit or inactivated vaccine within 14 days before the vaccination with trial vaccine. - under anti tuberculosis treatment. - not be able to follow the protocol, or not be able to understand the informed consent according to the researcher's judgment, due to various medical, psychological, social or other conditions.